View Older Stories View More Recent Stories

Feb 19, 2021 04:50PM Form SC 13D Pharvaris N.V. Filed by: venBio Global Strategic Fund III, L.P.
Feb 16, 2021 05:26PM Form SC 13G Harmony Biosciences Hold Filed by: venBio Global Strategic Fund II L.P.
Feb 16, 2021 05:25PM Form 13F-HR venBio Partners LLC For: Dec 31
Feb 16, 2021 05:10PM Form SC 13G Metacrine, Inc. Filed by: venBio Global Strategic Fund, L.P.
Jan 8, 2021 03:00AM Positive Phase 2b ICONA Interim Results for icosabutate in NASH Patients
Dec 8, 2020 08:00AM RayzeBio Completes $105M Series B Financing to Advance Targeted Radiopharmaceuticals for Cancer
Dec 6, 2020 10:00AM Attralus Presents Clinical Data from Novel, Potential First-in-Class Diagnostic AT-01 for Systemic Amyloidosis at Virtual ASH 2020
Dec 1, 2020 07:00AM Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer
Nov 19, 2020 04:00AM NorthSea Therapeutics doses first patient in Phase 1 trial of SEFA-1024 in dyslipidemia and further expands its clinical pipeline
Nov 18, 2020 08:00AM Pharvaris Announces $80 Million Series C Financing to Advance Novel Oral Bradykinin-B2-Receptor Antagonists for the Treatment of HAE
Nov 18, 2020 07:00AM Elevation Oncology Announces $65M Series B Financing and Promotion of Founder Shawn M. Leland to Chief Executive Officer
Nov 16, 2020 04:27PM Form 13F-HR venBio Partners LLC For: Sep 30
Nov 5, 2020 09:00AM Attralus to Present Clinical Data at Upcoming Virtual ASH 2020
Nov 3, 2020 12:50PM Form D OCA venBio III Segregate
Nov 3, 2020 11:31AM Form D OCA venBio III LLC
Oct 27, 2020 04:05PM PPD Reports Third Quarter and Year to Date 2020 Results
Oct 14, 2020 09:00AM Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Live Attenuated Vaccine Candidates
Oct 14, 2020 08:00AM RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics
Oct 6, 2020 03:19PM Form SC 13G Checkmate Pharmaceutical Filed by: venBio Global Strategic Fund II L.P.
Oct 1, 2020 10:02AM Form SC 13D ALX ONCOLOGY HOLDINGS Filed by: venBio Global Strategic Fund II L.P.
Sep 22, 2020 05:22PM Form 4 Metacrine, Inc. For: Sep 18 Filed by: venBio Global Strategic GP, Ltd.
Sep 15, 2020 08:56PM Form 3 Metacrine, Inc. For: Sep 15 Filed by: venBio Global Strategic Fund, L.P.
Sep 14, 2020 02:57PM Attralus Presents Preclinical and Clinical Data at 17th International Symposium on Amyloidosis
Sep 14, 2020 07:00AM Attralus Launches with $25 Million Series A Financing from venBio Partners to Transform Treatment for Patients with Systemic Amyloidosis
Sep 9, 2020 05:27PM Form SC 13D/A Akero Therapeutics, Inc. Filed by: venBio Global Strategic Fund II L.P.
Aug 14, 2020 04:50PM Form 13F-HR venBio Partners LLC For: Jun 30
Aug 12, 2020 09:01PM Form 4 Checkmate Pharmaceutical For: Aug 11 Filed by: venBio Global Strategic Fund II L.P.
Aug 6, 2020 09:04PM Form 3 Checkmate Pharmaceutical For: Aug 06 Filed by: venBio Global Strategic Fund II L.P.
Aug 4, 2020 04:05PM PPD Reports Second Quarter and Year to Date 2020 Results
Jul 21, 2020 09:30PM Form 4 ALX ONCOLOGY HOLDINGS For: Jul 21 Filed by: venBio Global Strategic GP, Ltd.
Jul 16, 2020 07:39PM Form 3 ALX ONCOLOGY HOLDINGS For: Jul 16 Filed by: venBio Global Strategic GP II, L.P.
Jul 9, 2020 05:28PM Form SC 13D/A PRECISION BIOSCIENCES Filed by: venBio Global Strategic Fund, L.P.
Jul 8, 2020 03:58PM Form SC 13D/A Akero Therapeutics, Inc. Filed by: venBio Global Strategic Fund, L.P.
Jun 26, 2020 12:00AM Artiva Biotherapeutics Launches with $78 Million Series A Financing to Advance NK Cell Therapies to Treat Cancer
Jun 24, 2020 05:26PM Form SC 13D/A PRECISION BIOSCIENCES Filed by: venBio Global Strategic Fund, L.P.
Jun 10, 2020 07:00AM Checkmate Pharmaceuticals Secures $85 Million in Series C Financing
Jun 9, 2020 08:00AM NFlection Therapeutics Launches with $20M Series A Funding to Advance Lead Program in Neurofibromatosis
Jun 8, 2020 02:46PM Form SC 13D/A PRECISION BIOSCIENCES Filed by: venBio Global Strategic Fund, L.P.
May 28, 2020 10:00AM AXONIS Therapeutics, Inc. Announces Seed Financing for Preclinical Development of Neuromodulating KCC2 Therapy
May 26, 2020 03:56PM Form 13F-HR venBio Partners LLC For: Dec 31
May 20, 2020 05:24PM Form 13F-HR/A venBio Partners LLC For: Dec 31
May 20, 2020 05:23PM Form 13F-HR/A venBio Partners LLC For: Sep 30
May 20, 2020 05:22PM Form 13F-HR/A venBio Partners LLC For: Mar 31
May 20, 2020 05:22PM Form 13F-HR/A venBio Partners LLC For: Jun 30
May 15, 2020 04:20PM Form 13F-HR venBio Partners LLC For: Mar 31
May 6, 2020 04:01PM PPD Reports First Quarter 2020 Results
Apr 16, 2020 12:47PM Form SC 13D/A Menlo Therapeutics Inc. Filed by: venBio Global Strategic Fund II L.P.
Apr 3, 2020 08:00AM venBio Closes $394 Million Life Sciences Venture Capital Fund
Mar 26, 2020 05:22PM Form D/A venBio Global Strategic
Mar 4, 2020 04:01PM PPD Reports Fourth Quarter and Full Year 2019 Results
View More Recent Stories View Older Stories